Theriva Biologics Doses First Patient In VIRAGE2 Phase 2a Clinical Trial, Small Proof-Of-Concept Study Evaluating More Frequent Repeated Dosing Of VCN-01 In First-Line Metastatic PDAC Patients Treated With Gemcitabine/Nab-Paclitaxel Chemotherapy

Loading news article.

Theriva Biologics Doses First Patient In VIRAGE2 Phase 2a Clinical Trial, Small Proof-Of-Concept Study Evaluating More Frequent Repeated Dosing Of VCN-01 In First-Line Metastatic PDAC Patients Treated With Gemcitabine/Nab-Paclitaxel Chemotherapy | WAPE

Theriva Biologics Doses First Patient In VIRAGE2 Phase 2a Clinical Trial, Small Proof-Of-Concept Study Evaluating More Frequent Repeated Dosing Of VCN-01 In First-Line Metastatic PDAC Patients Treated With Gemcitabine/Nab-Paclitaxel Chemotherapy

Article summary

Related companies

Comments —